NSEAcquisition12 Sept 2026 · 12 Sept 2026, 12:41 pm

Acquisition

Aurobindo Pharma Limited · AUROPHARMA

✦ AI SummaryM&A

Aurobindo Pharma Limited has informed the Exchange about the acquisition of A1 Biochem USA Inc, a wholly owned subsidiary of A1 Biochem Labs (India) Private Limited, which is a subsidiary of the Company. The acquisition is part of the earlier disclosed acquisition of A1 Biochem Group.

Analysis Scores

Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Aurobindo Pharma Limited has informed the Exchange about Acquisition

Attachments (1)

📄

AUROPHARMA_12092026124039_LtrToSEsA1Biochem12092026.pdf

pdf

Download →
View document text
September 12, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Further to our communication dated July 23, 2026, regarding the acquisition of the A1 Biochem Group, this is to inform you that A1 Biochem Labs (India) Private Limited, a step down subsidiary of the Company has subscribed to 10,000 equity shares of USD 100 (Hundred Only) each of ‘A1 Biochem USA Inc’ in USA on September 11, 2026. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as ‘Annexure A’. This is for your information and records. Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Enclosures: Annexure A Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 Telangana., India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Annexure ·A Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 a) Name of the target entity, details in brief such Name: A1 Biochem USA Inc as size, turnover etc.; Turnover: Not applicable as the company is yet to commence business b) Whether the acquisition would fall within A1 Biochem USA Inc is a wholly owned subsidiary of A1 related party transaction(s) and whether the Biochem Labs (India) Private Limited. A1 Biochem Labs promoter / promoter group / group companies India Private Limited is a subsidiary of Apitoria Pharma have any interest in the entity being acquired? If Private Limited, a wholly owned subsidiary of the yes, nature of interest and details thereof and Company and therefore is a related party of the whether the same is done at "arms-length"; Company. Promoters and promoter group of the Company are not interested in the transaction c) Industry to which the business of the target Pharmaceuticals entity being acquired belongs; d) Objects and effects of acquisition (including The object of this subsidiary is to undertake the but not limited to, disclosure of reasons for Contract Research and Development services business acquisition of target entity, if its business is as part of the acquisition of A1 Biochem Group earlier outside the main line of business of the listed disclosed on July 23, 2026. entity); e) Brief details of any governmental or regulatory No governmental or regulatory approvals required. approvals required for the acquisition. f) Indicative time period for completion of the Not applicable acquisition. g) Nature of consideration - whether cash 100% subscription to the share capital in cash consideration or share swap or any other form and details of the same; h) Cost of acquisition and / or the price at which The Company has subscribed to the Initial subscription the shares are acquired; New Subsidiary was share capital of USD 1,000,000 on September 11, 2026 incorporated. divided into 10,000 equity shares of USD 100 each. i) Percentage of shareholding / control acquired 100% and or number of shares acquired; j) Brief background about the entity acquired in This is a newly incorporated company and therefore the terms of products/line of business acquired, date history of the last 3 years’ turnover is not available. of incorporation, history of last 3 years turnover, country in which the acquired entity has This company shall be carrying out Contract Research presence and any other significant information and Development services business from USA (in brief); A1 Biochem USA Inc was incorporated on August 27, 2026 in USA Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 Telangana., India Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com